Abstract
Contraceptive options for women have expanded with the FDA approval of a monthly injectable contraceptive. Containing a progestin and estrogen (25 mg medroxyprogesterone acetate and 5 mg estradiol cypionate; Lunelle(TM)/Lunella(TM); Pharmacia and Upjohn), this novel once-a-month injection is characterized by the convenience and contraceptive efficacy of long-term reversible methods and the cycle control, return to fertility and side-effect profiles common to low-dose oral contraceptives. The association of these desirable attributes may increase the likelihood that a woman's chosen method will be used consistently and correctly to reduce the frequency of unintended pregnancy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 190-194 |
| Number of pages | 5 |
| Journal | International journal of fertility and women's medicine |
| Volume | 45 |
| Issue number | 2 |
| State | Published - Mar 2000 |
Keywords
- Contraceptive
- Estrogen
- Injectable
- Monthly
- Progestin
ASJC Scopus subject areas
- Reproductive Medicine
- Obstetrics and Gynecology
